You are here

Aptamer-based Nanofunctionalized OFET Biosensors

Award Information
Agency: Department of Defense
Branch: Air Force
Contract: FA8650-16-C-5410
Agency Tracking Number: F14A-T11-0051
Amount: $749,962.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: AF14-AT11
Solicitation Number: 2014.0
Timeline
Solicitation Year: 2014
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-02-03
Award End Date (Contract End Date): 2018-05-01
Small Business Information
2750 Indian Ripple Road
Dayton, OH 45440
United States
DUNS: 130020209
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Dr. Brian Henslee
 (937) 320-1877
 hensleeb@crgrp.com
Business Contact
 Ms. Chrysa Theodore
Phone: (937) 320-1877
Email: theodorecm@crgrp.com
Research Institution
N/A
Abstract

ABSTRACT: Researchers are identifying new biomarkers to help monitor, diagnose, and treat growing threats to the human body and enhance human performance. Recent sensor work combining biorecognition elements with field effect transistors (bio-FETs) has been shown sensitive and selective to biomarkers in the picomolar range with continuous detection; however device-to-device performance variability, reliability, and scaled manufacturing remain a challenge. For practical applications, device variability should be less than 10% for a reliable sensor in practical applications. Materials used in fabrication of bio-FET platforms also need to be cost effective and scalable for mass production. CRG proposes a water stable organic FET (OFET) based biosensor. In Phase I CRG demonstrated a base OFET platform from scalable solution processable materials that can achieved less than 10% variability in device performance. This base OFET platform could be functionalized with different materials that allow the conjugation of a variety of biorecognition elements. CRG demonstrated the platform in multiple sensor applications including a biosensor. The base OFET platform also has the potential for compatibility printed electronics manufacturing processes. In Phase II CRG will optimize the platform for a specific biomarker and scale device production to achieve a reliable and reproducible biomarker sensor for practical applications.; BENEFIT: Operational Benefits: (1) Extremely low detection limits (picomolar) (2) Water stable (3) Scalable materials for flexible printed electronics (4) Reliable and low variability device performance (5) Long term stability and continuous detection Commercial Applications: (1) Environmental monitoring (2) Multiplex healthcare diagnostics (3) Point of care diagnostics

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government